This is partly because most of the retinoblastoma patients at MSKCC received treatment that preserved their vision, and in this study we deliberately included patients who have tumor samples available as a result of eye enucleation such that we can compare the RB1 mutation status in plasma with tumor. The gene discussed is RB1; the disease is retinoblastoma.